A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Enpatoran on the QTc (Corrected QT) Interval in Healthy Adult Participants

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Enpatoran (Primary) ; Moxifloxacin
Indications COVID-19 pneumonia; Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Systemic lupus erythematosus
Focus Therapeutic Use
Sponsors Merck KGaA

03 Dec 2024 Planned End Date changed from 1 Mar 2025 to 4 Dec 2024.
03 Dec 2024 Planned primary completion date changed from 1 Mar 2025 to 4 Dec 2024.
03 Dec 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com